ENOV ENOVIS CORPORATION

Enovis Introduces the DonJoy ROAM™ OA Knee Brace

Enovis Introduces the DonJoy ROAM™ OA Knee Brace

The newest innovation in unloader braces is comfortable, easy to use and effective.

WILMINGTON, DE, Jan. 25, 2024 (GLOBE NEWSWIRE) --  Enovis™ Corporation (“Enovis” or the “Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, announced today that its DJO, LLC subsidiary has launched its new DonJoy® ROAM™ OA knee brace for patients with osteoarthritis or other knee pain and instability.

ROAM OA is the latest innovation in unloader technology, unloading the pressure of unicompartmental osteoarthritis and shifting weight away from the affected knee to dynamically relieve pain, improve stability and help improve mobility. Designed for conservative care, preparation for surgery, or for postoperative knee protection, ROAM OA is ideal for a wide range of patients who want to maintain or increase activity.

“By the time osteoarthritis patients actually seek medical care, they usually have a significant amount of pain,” said orthopedic surgeon and pro sports team physician Brian J. Cole, MD. “Braces like the ROAM OA can provide the support and relief patients need to get back to the activities they love, without having surgery.”

Patient-friendly features make ROAM OA effective, comfortable and easy to use:

  • “Mag-align” magnetic clips help easily align the strap connection points to enhance patient confidence, even with eyesight or dexterity challenges.
  • “Set-and-Forget” technology allows patients to easily put the brace on and off without changing any provider settings.
  • BOA® Fit System lets patients easily dial up or down to adjust support and pain relief on demand.
  • Slim profile hinge design allows the brace to be worn confidently beneath clothing.
  • Dynamic strapping and unique condyle harness completely avoids sensitive skin in the popliteal (back of the knee) space, while providing comfortable pressure to activate proprioception on the opposite side of the knee with maximal unloading during extension.
  • Anti-migration technology uses soft silicone keeping the brace comfortably in place.
  • 2X Cool Technology fibers feel comfortable on the skin by keeping the surface 2 degrees cooler than the environment.
  • Unique design fits either left lateral and right medial, or vice versa, in only six SKUs compared to a traditional brace that needs as many as 56 SKUs to achieve the same range of patient fit.
  • Additionally, a custom-fabricated brace option addresses challenging fit needs with an optimal height setting, cuff sizing and strap lengths that provide maximum comfort and mitigate migration. Optional extension and flexion control meet each patient’s specific needs.

“ROAM OA represents the next generation of unloader knee braces for active patients with pain due to osteoarthritis or other causes," said Terry Ross, Group President of Enovis Prevention & Recovery. “It’s effective and easy for patients to use and easy for providers to prescribe, even for patients who would otherwise need a customized device.”

For more information about the ROAM OA knee brace, visit .





About Enovis™

Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services and integrated technologies fuel active lifestyles in orthopedics and beyond. For more information about Enovis, please visit .



Brian J. Cole, MD, MBA is a consultant for DJO, LLC.

BOA® is a registered trademark of Boa Technology, Inc.





Investor Relations Contact

Kyle Rose

Vice President, Investor Relations

Enovis Corporation





Media Contact

Leda Buster

Director of Marketing Communications, Bracing and Supports

Enovis Corporation

 



Attachment



EN
25/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ENOVIS CORPORATION

 PRESS RELEASE

Enovis Announces First Quarter 2025 Results

Enovis Announces First Quarter 2025 Results Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12th, 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an ...

 PRESS RELEASE

Enovis to Host First Quarter 2025 Results Conference Call on May 8th

Enovis to Host First Quarter 2025 Results Conference Call on May 8th Wilimington, DE, April 17, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, 2025 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at . Conference Call/We...

 PRESS RELEASE

Enovis Announces Appointment of Damien McDonald as Chief Executive Off...

Enovis Announces Appointment of Damien McDonald as Chief Executive Officer Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “The Company”) (NYSE: ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company’s 2025 Annual Meeting of Stockholde...

 PRESS RELEASE

Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS...

Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025 Alongside an evidence-based portfolio, Enovis will showcase how it’s “Redefining Every Step” with confidence-building education and a partnership that goes beyond the product; attendees invited to exclusive events. WILMINGTON, DE, March 25, 2025 (GLOBE NEWSWIRE) -- Enovis™ (NYSE: ENOV), a global medical technology innovator, will feature its expanding portfolio of foot and ankle solutions at this year’s American College of Foot & Ankle Surgeons (ACFAS) Annual Scientific Conference in Phoenix, Ariz., taking plac...

 PRESS RELEASE

Enovis to Participate in Upcoming Investor Conferences

Enovis to Participate in Upcoming Investor Conferences Wilmington, DE, March 05, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Canaccord Genuity Musculoskeletal Conference: Ben Berry, Chief Financial Officer, and Louie Vogt, Group President - Recon, will participate in a fireside chat on Monday, March 10th at 10:00 a.m. Pacific Time.37th Annual Roth Conference: Louie Vogt, Group President - Recon, will participate in a fi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch